日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

From bench to bedside, blade, and back: FAP expression in juvenile angiofibroma. Potential implications for FAPI-PET/CT imaging and targeted therapy?

从实验室到临床，再到手术刀，最终回归实验室：FAP在青少年血管纤维瘤中的表达。对FAPI-PET/CT成像和靶向治疗的潜在意义？

期刊:European Journal of Nuclear Medicine and Molecular Imaging
影响因子:7.6
doi:10.1007/s00259-025-07468-9
Pillong Lukas, Burgard Caroline, Rosar Florian, Demirkol Betül, Ebner Rafail, Linxweiler Maximilian, Bozzato Alessandro, Schick Bernhard, Wemmert Silke
心血管
FAP
发表日期：2026
文献求助 收藏

Horizontal transfer of post-translational modifiers brings evolutionary opportunity and challenges to a conserved translation factor

翻译后修饰基因的水平转移为保守的翻译因子带来了进化机遇和挑战。

期刊:BMC Biology
影响因子:4.5
doi:10.1186/s12915-026-02531-9
Brewer, Tess E; Kielkowski, Pavel; Stritzel, Jingzhi; Meier-Rosar, Florian; Schlundt, Andreas; Lassak, Jürgen
发表日期：2026
文献求助 收藏

Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression

剂量学分析表明，在PSMA高表达的非前列腺癌中，[¹⁷⁷Lu]Lu-PSMA-617清除迅速且吸收剂量低。

期刊:Ejnmmi Research
影响因子:3
doi:10.1186/s13550-026-01394-z
Khreish, Fadi; Rosar, Florian; Burgard, Caroline; Petto, Sven; Maus, Stephan; Stemler, Tobias; Bartholomä, Mark; Sabet, Amir; Schaefer-Schuler, Andrea; Ezziddin, Samer
肿瘤
前列腺癌
肿瘤免疫
发表日期：2026
文献求助 收藏

Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience

使用[¹⁷⁷Lu]Lu-PSMA-617放射性配体进行单剂量多西他赛增强靶向放射性核素治疗治疗难治性转移性去势抵抗性前列腺癌的疗效和安全性：一项试点研究的初步证据

期刊:Ejnmmi Research
影响因子:3
doi:10.1186/s13550-026-01408-w
Ebert, Niklas; Rosar, Florian; Burgard, Caroline; Bartholomä, Mark; Maus, Stephan; Hein, Connor; Blickle, Arne; Ezziddin, Samer; Khreish, Fadi
肿瘤
前列腺癌
肿瘤免疫
发表日期：2026
文献求助 收藏

Auger Emitting [(161)Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal Carcinomatosis

俄歇发射[(161)Tb]Tb-PSMA-617放射性配体疗法治疗伴有腹膜癌的转移性去势抵抗性前列腺癌

期刊:Nuclear Medicine and Molecular Imaging
影响因子:2.7
doi:10.1007/s13139-025-00973-7
Rosar, Florian; Blickle, Arne; Bastian, Moritz B; Speicher, Tilman; Schaefer-Schuler, Andrea; Burgard, Caroline; Maus, Stephan; Ezziddin, Samer
肿瘤
前列腺癌
肿瘤免疫
发表日期：2026
文献求助 收藏

Visceral Leishmaniasis in Southern Brazil: an overview of current epidemiology

巴西南部内脏利什曼病：当前流行病学概述

期刊:Revista Da Sociedade Brasileira De Medicina Tropical
影响因子:2.3
doi:10.1590/0037-8682-0240-2025
Dambrós, Bibiana Paula; Rosar, Amabilli de Souza; Stoco, Patricia Hermes; Quaresma, Patricia Flávia; Grisard, Edmundo Carlos; Steindel, Mario
发表日期：2026
文献求助 收藏

RETICULATA1 is a plastid-localized basic amino acid transporter

RETICULATA1 是一种定位于质体的基本氨基酸转运蛋白

期刊:Nature Plants
影响因子:13.6
doi:10.1038/s41477-025-02080-z
Kuhnert, Franziska; Westhoff, Philipp; Valencia, Vanessa; Krüger, Stephan; Vogel, Karolina; Lundquist, Peter K; Rosar, Christian; Goss, Tatjana; Weber, Andreas P M
LAT
RET
发表日期：2025
文献求助 收藏

Pilot experience of [(161)Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry

在前瞻性注册研究中，对接受常规PSMA放射性激光治疗的转移性去势抵抗性前列腺癌（mCRPC）患者进行[(161)Tb]Tb-PSMA-617放射性激光治疗的试点研究结果显示，在接受常规PSMA放射性激光治疗后，转移性去势抵抗性前列腺癌（mCRPC）患者接受[(161)Tb]Tb-PSMA-617放射性激光治疗后，患者在接受[(161)Tb]Tb-PSMA-617放射性激光

期刊:Theranostics
影响因子:13.3
doi:10.7150/thno.115831
Rosar, Florian; Burgard, Caroline; Petrescu, Christine; Blickle, Arne; Bartholomä, Mark; Maus, Stephan; Bastian, Moritz B; Speicher, Tilman; Schaefer-Schuler, Andrea; Ezziddin, Samer
肿瘤
前列腺癌
肿瘤免疫
CRP
发表日期：2025
文献求助 收藏

[(68)Ga]Ga-FAPI-04 PET/CT in a patient with endometriosis: a potential game changer?

[(68)Ga]Ga-FAPI-04 PET/CT 在子宫内膜异位症患者中的应用：一项潜在的变革性技术？

期刊:European Journal of Nuclear Medicine and Molecular Imaging
影响因子:7.6
doi:10.1007/s00259-025-07252-9
Burgard, Caroline; Rosar, Florian; Ezziddin, Samer; Hamoud, Bashar H; Solomayer, Erich-Franz; Laschke, Matthias W; Constantin, Alin; Bartholomä, Mark
FAP
发表日期：2025
文献求助 收藏

Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3)

扩大 PSMA-RLT 的应用范围：评估对体能状态较差（ECOG 3）的难治性 mCRPC 患者的治疗效果

期刊:European Journal of Nuclear Medicine and Molecular Imaging
影响因子:7.6
doi:10.1007/s00259-025-07346-4
Bastian, Moritz B; Wörl, Benedikt; Blickle, Arne; Burgard, Caroline; Speicher, Tilman; Bartholomä, Mark; Schaefer-Schuler, Andrea; Maus, Stephan; Ezziddin, Samer; Rosar, Florian
CRP
发表日期：2025
文献求助 收藏